Stay updated on Nivolumab in AML Remission at High Risk Clinical Trial
Sign up to get notified when there's something new on the Nivolumab in AML Remission at High Risk Clinical Trial page.
Latest updates to the Nivolumab in AML Remission at High Risk Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedRevision notice updated from v3.3.1 to v3.3.2 across the page footer, indicating a minor site update that does not affect study content or usability. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check15 days agoChange DetectedA new note clarifying that publications are automatically filled from PubMed and may not be about the study was added, and the footer revision label changed from v3.2.0 to v3.3.1.SummaryDifference0.1%
- Check22 days agoChange DetectedThe site-wide funding-status notice was removed; no core study information was altered. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%
- Check37 days agoChange DetectedUpdated the Study Details page to include results-related sections and new timing information. Dates for enrollment, primary completion, and study completion have been updated.SummaryDifference0.4%
- Check65 days agoChange DetectedThe page now includes a government-funding lapse notice and a new v3.2.0 update, replacing the old v3.1.0 tag.SummaryDifference3%
- Check73 days agoChange DetectedPage revision updated from v3.0.2 to v3.1.0, indicating a version bump with no other substantive changes.SummaryDifference0.1%
Stay in the know with updates to Nivolumab in AML Remission at High Risk Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab in AML Remission at High Risk Clinical Trial page.